Recently, I wrote about domestic and foreign dividend paying small-and midcaps that could give investors a bigger opportunity for rising returns via a small capitalization. The disadvantage is definitely the higher risks.
With the Standard
& Poor’s 500 having tripled off its financial-crisis low to trade near
an all-time high, investors have started to look overseas for cheap stocks.
Big money flooded
the European market within recent months and pushed the local stock markets in
Europe.
While the Euro is
still in a down trend, the current QE program of the ECB could lead to further
fire power on the market.
Attached are 4 big names from the old country with deep values and solid dividends. Most of the
results come from the healthcare sector, especially from the pharmacy industry.
These are the results:
GlaxoSmithKline -- Yield: 5.66%
GlaxoSmithKline (NYSE:GSK) employs 98,702 people, generates revenue of $36,167.84 million and has a net income of $4,450.63 million. The current market capitalization stands at $108.88 billion.GlaxoSmithKline’s earnings before interest, taxes, depreciation and amortization (EBITDA) amounts to $10,380.61 million. The EBITDA margin is 28.70% (the operating margin is 15.64% and the net profit margin 12.31%).
Financials: The total debt represents 46.21% of GlaxoSmithKline assets and the total debt in relation to the equity amounts to 440.63%. Due to the financial situation, a return on equity of 48.95% was realized by GlaxoSmithKline.
Twelve trailing months earnings per share reached a value of $6.63. Last fiscal year, GlaxoSmithKline paid $2.52 in the form of dividends to shareholders.
Market Valuation: Here are the price ratios of the company: The P/E ratio is 6.75, the P/S ratio is 3.01 and the P/B ratio is finally 16.25. The dividend yield amounts to 5.66%.
Stock Charts:
 |
| Long-Term Stock Price Chart of GlaxoSmithKline (GSK) |
 |
| Long-Term Dividend Payment History of GlaxoSmithKline (GSK) |
 |
| Long-Term Dividend Yield History of GlaxoSmithKline (GSK) |
Sanofi -- Yield: 3.20%
Sanofi (NYSE:SNY) employs 113,496 people, generates revenue of $39,058.04 million and has a net income of $5,221.63 million. The current market capitalization stands at $132.09 billion.Sanofi’s earnings before interest, taxes, depreciation and amortization (EBITDA) amounts to $11,813.95 million. The EBITDA margin is 30.25% (the operating margin is 18.01% and the net profit margin 13.37%).
Financials: The total debt represents 15.21% of Sanofi assets and the total debt in relation to the equity amounts to 26.40%. Due to the financial situation, a return on equity of 7.77% was realized by Sanofi.
Twelve trailing months earnings per share reached a value of $1.87. Last fiscal year, Sanofi paid $0.90 in the form of dividends to shareholders.
Market Valuation: Here are the price ratios of the company: The P/E ratio is 26.95, the P/S ratio is 3.38 and the P/B ratio is finally 2.06. The dividend yield amounts to 3.20%.
Stock Charts:
 |
| Long-Term Stock Price Chart of Sanofi (SNY) |
 |
| Long-Term Dividend Payment History of Sanofi (SNY) |
 |
| Long-Term Dividend Yield History of Sanofi (SNY) |
Novartis -- Yield: 2.57%
Novartis (NYSE:NVS) employs 133,413 people, generates revenue of $53,634.00 million and has a net income of $10,727.00 million. The current market capitalization stands at $278.38 billion.Novartis’s earnings before interest, taxes, depreciation and amortization (EBITDA) amounts to $16,872.00 million. The EBITDA margin is 31.46% (the operating margin is 20.68% and the net profit margin 20.00%).
Financials: The total debt represents 16.24% of Novartis assets and the total debt in relation to the equity amounts to 28.77%. Due to the financial situation, a return on equity of 14.69% was realized by Novartis.
Twelve trailing months earnings per share reached a value of $4.33. Last fiscal year, Novartis paid $2.76 in the form of dividends to shareholders.
Market Valuation: Here are the price ratios of the company: The P/E ratio is 23.98, the P/S ratio is 5.19 and the P/B ratio is finally 3.52. The dividend yield amounts to 2.57%.
Stock Charts:
 |
| Long-Term Stock Price Chart of Novartis (NVS) |
 |
| Long-Term Dividend Payment History of Novartis (NVS) |
 |
| Long-Term Dividend Yield History of Novartis (NVS) |
Akzo Nobel -- Yield: 2.16%
Akzo Nobel (AMS:AKZA) employs 46,400 people, generates revenue of $14,296.00 million and has a net income of $600.00 million. The current market capitalization stands at $16.12 billion.Akzo Nobel’s earnings before interest, taxes, depreciation and amortization (EBITDA) amounts to $1,943.00 million. The EBITDA margin is 13.59% (the operating margin is 6.90% and the net profit margin 4.20%).
Financials: The total debt represents 20.48% of Akzo Nobel assets and the total debt in relation to the equity amounts to 57.65%. Due to the financial situation, a return on equity of 9.28% was realized by Akzo Nobel.
Twelve trailing months earnings per share reached a value of $2.30. Last fiscal year, Akzo Nobel paid $1.23 in the form of dividends to shareholders.
Market Valuation: Here are the price ratios of the company: The P/E ratio is 28.85, the P/S ratio is 1.14 and the P/B ratio is finally 2.85. The dividend yield amounts to 2.16%.
Stock Charts:
 |
| Long-Term Stock Price Chart of Akzo Nobel (AKZA) |
 |
| Long-Term Dividend Payment History of Akzo Nobel (AKZA) |
 |
| Long-Term Dividend Yield History of Akzo Nobel (AKZA) |
